Dimensional Fund Advisors LP Has $223.50 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Dimensional Fund Advisors raised its stake in Zimmer Biomet to 2,269,122 shares (about 1.14% of the company) worth roughly $223.5 million after adding 39,146 shares in Q3.
• Zimmer Biomet beat quarterly expectations with $2.42 EPS and $2.24 billion revenue (up 10.9% YoY), set FY2026 guidance of 8.300–8.450 EPS, and announced a quarterly dividend of $0.24 (1.0% yield).
• Analysts are mixed: the consensus rating is Hold with a $106.20 price target, reflecting a range of opinions (1 Strong Buy, 8 Buy, 10 Hold, 3 Sell).

Dimensional Fund Advisors LP lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,269,122 shares of the medical equipment provider's stock after purchasing an additional 39,146 shares during the quarter. Dimensional Fund Advisors LP owned about 1.14% of Zimmer Biomet worth $223,503,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ZBH. Legacy Wealth Asset Management LLC grew its stake in shares of Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider's stock worth $460,000 after acquiring an additional 106 shares in the last quarter. Global Retirement Partners LLC lifted its position in shares of Zimmer Biomet by 7.0% in the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider's stock worth $166,000 after purchasing an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Generali Asset Management SPA SGR boosted its holdings in Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider's stock worth $1,402,000 after purchasing an additional 122 shares during the last quarter. Finally, Brookstone Capital Management grew its position in Zimmer Biomet by 1.3% in the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider's stock valued at $921,000 after purchasing an additional 123 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 11th. Sanford C. Bernstein lifted their target price on Zimmer Biomet from $97.00 to $99.00 and gave the company a "market perform" rating in a research report on Friday, January 9th. Barclays dropped their target price on Zimmer Biomet from $104.00 to $100.00 and set an "underweight" rating on the stock in a report on Thursday, February 12th. Robert W. Baird reissued a "neutral" rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Finally, Wall Street Zen lowered Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus price target of $106.20.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $94.08 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44. The firm has a market capitalization of $18.41 billion, a price-to-earnings ratio of 26.58, a P/E/G ratio of 1.92 and a beta of 0.58. The stock's 50 day moving average price is $92.13 and its two-hundred day moving average price is $95.67. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the previous year, the company posted $2.31 EPS. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet's dividend payout ratio is presently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.